A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: A report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901

Riichiroh Maruyama, Noriyuki Ebi, Junji Kishimoto, Masato Kato, Tokujiro Yano, Yoshinori Nagamatsu, Shuichi Tsukamoto, Shinji Akamine, Sho Saeki, Yukito Ichinose

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The present study was designed to determine whether adjuvant chemotherapy with S-1 after surgical resection is feasible in elderly patients with non-small cell lung cancer (NSCLC), using a multi-institutional trial. Methods: From July 2009 to July 2011, 25 patients received the following regimen: 2 weeks of administration and 1 week of withdrawal of S-1 at 50-100 mg/body per day in an outpatient setting. The primary endpoint of this trial was the completion rate of eight cycles. Results: The completion rate of eight cycles was 70.8 % [95 % confidence interval (CI) 52.7-89.0 %]. The perfect completion rate of eight cycles on schedule with full doses without delays was 50 % (95 % CI 30.0-70.0 %). The reasons for incomplete cycles were: patient refusal in four cases, anorexia in two cases and thrombocytopenia in one case. As a consequence of delays and/or dose reductions, the relative dose intensity of S-1 was 76.3 %. Conclusions: Adjuvant chemotherapy with S-1 at a reduced dose and schedule was therefore found to be a feasible treatment for elderly Japanese patients who had undergone surgical resection for NSCLC (UMIN Clinical Trials Registry number UMIN000002383).

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume19
Issue number1
DOIs
Publication statusPublished - Feb 1 2014

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Lung
Appointments and Schedules
Confidence Intervals
Anorexia
Thrombocytopenia
Registries
Outpatients
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer : A report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901. / Maruyama, Riichiroh; Ebi, Noriyuki; Kishimoto, Junji; Kato, Masato; Yano, Tokujiro; Nagamatsu, Yoshinori; Tsukamoto, Shuichi; Akamine, Shinji; Saeki, Sho; Ichinose, Yukito.

In: International Journal of Clinical Oncology, Vol. 19, No. 1, 01.02.2014, p. 57-62.

Research output: Contribution to journalArticle

Maruyama, Riichiroh ; Ebi, Noriyuki ; Kishimoto, Junji ; Kato, Masato ; Yano, Tokujiro ; Nagamatsu, Yoshinori ; Tsukamoto, Shuichi ; Akamine, Shinji ; Saeki, Sho ; Ichinose, Yukito. / A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer : A report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901. In: International Journal of Clinical Oncology. 2014 ; Vol. 19, No. 1. pp. 57-62.
@article{37aff41cc8e04ab095862b9ec3657eb3,
title = "A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: A report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901",
abstract = "Background: The present study was designed to determine whether adjuvant chemotherapy with S-1 after surgical resection is feasible in elderly patients with non-small cell lung cancer (NSCLC), using a multi-institutional trial. Methods: From July 2009 to July 2011, 25 patients received the following regimen: 2 weeks of administration and 1 week of withdrawal of S-1 at 50-100 mg/body per day in an outpatient setting. The primary endpoint of this trial was the completion rate of eight cycles. Results: The completion rate of eight cycles was 70.8 {\%} [95 {\%} confidence interval (CI) 52.7-89.0 {\%}]. The perfect completion rate of eight cycles on schedule with full doses without delays was 50 {\%} (95 {\%} CI 30.0-70.0 {\%}). The reasons for incomplete cycles were: patient refusal in four cases, anorexia in two cases and thrombocytopenia in one case. As a consequence of delays and/or dose reductions, the relative dose intensity of S-1 was 76.3 {\%}. Conclusions: Adjuvant chemotherapy with S-1 at a reduced dose and schedule was therefore found to be a feasible treatment for elderly Japanese patients who had undergone surgical resection for NSCLC (UMIN Clinical Trials Registry number UMIN000002383).",
author = "Riichiroh Maruyama and Noriyuki Ebi and Junji Kishimoto and Masato Kato and Tokujiro Yano and Yoshinori Nagamatsu and Shuichi Tsukamoto and Shinji Akamine and Sho Saeki and Yukito Ichinose",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/s10147-013-0516-y",
language = "English",
volume = "19",
pages = "57--62",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer

T2 - A report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901

AU - Maruyama, Riichiroh

AU - Ebi, Noriyuki

AU - Kishimoto, Junji

AU - Kato, Masato

AU - Yano, Tokujiro

AU - Nagamatsu, Yoshinori

AU - Tsukamoto, Shuichi

AU - Akamine, Shinji

AU - Saeki, Sho

AU - Ichinose, Yukito

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background: The present study was designed to determine whether adjuvant chemotherapy with S-1 after surgical resection is feasible in elderly patients with non-small cell lung cancer (NSCLC), using a multi-institutional trial. Methods: From July 2009 to July 2011, 25 patients received the following regimen: 2 weeks of administration and 1 week of withdrawal of S-1 at 50-100 mg/body per day in an outpatient setting. The primary endpoint of this trial was the completion rate of eight cycles. Results: The completion rate of eight cycles was 70.8 % [95 % confidence interval (CI) 52.7-89.0 %]. The perfect completion rate of eight cycles on schedule with full doses without delays was 50 % (95 % CI 30.0-70.0 %). The reasons for incomplete cycles were: patient refusal in four cases, anorexia in two cases and thrombocytopenia in one case. As a consequence of delays and/or dose reductions, the relative dose intensity of S-1 was 76.3 %. Conclusions: Adjuvant chemotherapy with S-1 at a reduced dose and schedule was therefore found to be a feasible treatment for elderly Japanese patients who had undergone surgical resection for NSCLC (UMIN Clinical Trials Registry number UMIN000002383).

AB - Background: The present study was designed to determine whether adjuvant chemotherapy with S-1 after surgical resection is feasible in elderly patients with non-small cell lung cancer (NSCLC), using a multi-institutional trial. Methods: From July 2009 to July 2011, 25 patients received the following regimen: 2 weeks of administration and 1 week of withdrawal of S-1 at 50-100 mg/body per day in an outpatient setting. The primary endpoint of this trial was the completion rate of eight cycles. Results: The completion rate of eight cycles was 70.8 % [95 % confidence interval (CI) 52.7-89.0 %]. The perfect completion rate of eight cycles on schedule with full doses without delays was 50 % (95 % CI 30.0-70.0 %). The reasons for incomplete cycles were: patient refusal in four cases, anorexia in two cases and thrombocytopenia in one case. As a consequence of delays and/or dose reductions, the relative dose intensity of S-1 was 76.3 %. Conclusions: Adjuvant chemotherapy with S-1 at a reduced dose and schedule was therefore found to be a feasible treatment for elderly Japanese patients who had undergone surgical resection for NSCLC (UMIN Clinical Trials Registry number UMIN000002383).

UR - http://www.scopus.com/inward/record.url?scp=84894569264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894569264&partnerID=8YFLogxK

U2 - 10.1007/s10147-013-0516-y

DO - 10.1007/s10147-013-0516-y

M3 - Article

C2 - 23354832

AN - SCOPUS:84894569264

VL - 19

SP - 57

EP - 62

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -